SWOG S0925: A randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1601-1608

  Yu, Evan Y ^a   Li, Hongli ^a   Higano, Celestia S ^a   Agarwal, Neeraj ^d   Pal, Sumanta K ^e   Alva, Ajjai ^g   Heath, Elisabeth I ^h   Lam, Elaine T ⁱ   Gupta, Shilpa ^j   Lilly, Michael B ^k   Inoue, Yoshio ^c   Chi, Kim N ^l   Vogelzang, Nicholas J ^m   Quinn, David I ^f   Cheng, Heather H ^a   Plymate, Stephen R ^b   Hussain, Maha ^o   Tangen, Catherine M ^a   Thompson, Ian M ⁿ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Multicare Regional Cancer Center   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m University of Texas Health Science Center at San Antonio ^*  (United States)

ⁿ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICALUTAMIDE; BIOLOGICAL MARKER; C PEPTIDE; CIXUTUMUMAB; CREATININE; GONADORELIN AGONIST; GROWTH HORMONE; INSULIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN III; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANILIDE; ANTI-IGF-1R ANTIBODY A12; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN; MONOCLONAL ANTIBODY; NITRILE; TOLUENESULFONIC ACID DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; ERECTILE DYSFUNCTION; FATIGUE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC HORMONE SENSITIVE PROSTATE CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; BLOOD; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; STATISTICAL MODEL; TUMOR EMBOLISM;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84933509575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.4127     Document Type: Article

References (20)

1. Wu J, Yu E: Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy. Cancer Metastasis Rev 33:607-617, 2014
2. Samani AA, Yakar S, LeRoith D, et al: The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28:20-47, 2007
3. Wu JD, Haugk K, Woodke L, et al: Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99:392-401, 2006
4. Wu JD, Odman A, Higgins LM, et al: In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11:3065-3074, 2005
5. Higano CS, Alumkal JJ, Ryan CJ, et al: A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody, against the insulin-like growth factor-1 receptor, as monotherapy in patients with metastatic, asymptomatic castration-resistant prostate cancer. J Clin Oncol 27:269s, 2009 (suppl; abstr 5142)
6. Higano CS, Alumkal JJ, Ryan CJ, et al: A phase II study of cixutumumab (IMC-A12), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer: Feasibility of every 3-week dosing and updated results. J Clin Oncol 28, 2010 (suppl; abstr 189)
7. Dean JP, Sprenger CC, Wan J, et al: Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: Effects of obesity and androgen deprivation. J Clin Endocrinol Metab 98:E820-E828, 2013
8. Chi KN, Gleave ME, Fazli L, et al: A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18:3407-3413, 2012
9. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006
10. Cheng HH, Mitchell PS, Kroh EM, et al: Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 8:e69239, 2013
11. Plymate SR, Haugk K, Coleman I, et al: An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 13:6429-6439, 2007
12. Corey E, Quinn JE, Buhler KR, et al: LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 55:239-246, 2003
13. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
14. Resel Folkersma L, San José Manso L, Galante Romo I, et al: Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 80:1328-1332, 2012
15. Goodman OB Jr, Symanowski JT, Loudyi A, et al: Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 9:31-38, 2011
16. Wu JD, Haugk K, Coleman I, et al: Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 12:6153-6160, 2006
17. Rathkopf DE, Danila DC, Chudow JJ, et al: Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of rapamycin (mTOR) inhibitor temsirolimus in metastatic castration-resistant prostate cancer. J Clin Oncol 28:41s, 2010 (suppl; abstr TPS242)
18. de Bono JS, Piulats JM, Pandha HS, et al: Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 20:1925-1934, 2014
19. Sweeney C, Chen YH, Carducci MA, et al: Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: An ECOG-led phase III randomized trial. J Clin Oncol 32:3s, 2014 (suppl 15s; abstr LBA2)
20. Cheng HH, Lin DW, Yu EY: Advanced clinical states in prostate cancer. Urol Clin North Am 39: 561-571, 2012